Biostar Pharmaceuticals, Inc. Expects 2013 Yearly Revenue Growth above 20% with Break Even Operating Results as Compared With

  Biostar Pharmaceuticals, Inc. Expects 2013 Yearly Revenue Growth above 20%
   with Break Even Operating Results as Compared With Last Year's USD$21.8
                         Million Loss from Operations

PR Newswire

XIANYANG, China, Feb. 20, 2014

XIANYANG, China, Feb. 20, 2014 /PRNewswire/ -- Biostar Pharmaceuticals, Inc.
(NASDAQ: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and
marketer of pharmaceutical and health supplement products in China for a
variety of diseases and conditions, today announced that its preliminary
estimate that, based on the Company's current review of the last fiscal year's
results, its 2013 revenue growth is expected to exceed by 20% year over year
while the Company expects to achieve break even or slightly profitable
operating results, as compared with a nearly USD$21.8 million loss from
operations in 2012. The Company is currently working with its auditors and
will report the audited 2013 year-end financial result following SEC
requirement.

The Company cautions shareholders and potential investors in the Company's
securities that the Company's independent public accountants, have not audited
or reviewed the above referenced amounts and that such financial information
is subject to further analysis and independent review. These results are
preliminary and are subject to change, possibly material in nature, following
completion of the audit for the year ended December 31, 2013.

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary and
controlled affiliate in China, develops, manufactures and markets
pharmaceutical and health supplement products for a variety of diseases and
conditions. The Company's most popular product is its Xin Aoxing Oleanolic
Acid Capsule, an over-the-counter medicine for chronic Hepatitis B, a disease
affecting approximately 10% of the Chinese population. For more information
please visit: http://www.biostarpharmaceuticals.com.

Safe Harbor Relating to the Forward-Looking Statements

Certain statements in this release concerning our future growth prospects are
forward-looking statements, within the meaning of Section 27A of the U.S.
Securities Act of 1933, as amended, and Section 21E of the U.S. Securities
Exchange Act of 1934, as amended, which involve a number of risks and
uncertainties that could cause actual results to differ materially from those
in such forward-looking statements. The company uses words and phrases such as
"guidance," "forecasted," "projects," "is expected," "remain confident,"
"will" and similar expressions to identify forward-looking statements in this
press release, including forward-looking statements. Undue reliance should not
be placed on forward-looking information. Forward-looking information is based
on current expectations, estimates and projections that involve a number of
risks, which could cause actual results to vary and in some instances to
differ materially from those anticipated by Biostar and described in the
forward-looking information contained in this news release. These results are
preliminary and are subject to change, possibly material in nature, following
completion of the audit for the year ended December 31, 2013. The risks and
uncertainties relating to these statements include, but are not limited to,
risks and uncertainties regarding the Company's ability to achieve the
projected sales in the recently opened sales offices, to complete the
contemplated clinical trials and capitalize on such opportunities, the
Company's ability to recover its sales and revenue for the gel capsule segment
of its business, the state of consumer confidence and market demand or the
Company's products, success of our investments, risks and uncertainties
regarding fluctuations in earnings, our ability to sustain our previous levels
of profitability including on account of our ability to manage growth, intense
competition, wage increases in China, our ability to attract and retain highly
skilled professionals, time and cost overruns on fixed-price, fixed-time frame
contracts, client concentration, our ability to successfully complete and
integrate potential acquisitions, withdrawal of governmental fiscal
incentives, political instability and regional conflicts and legal
restrictions on raising capital or acquiring companies outside China.
Additional risks that could affect our future operating results are more fully
described in our United States Securities and Exchange Commission filings
including our most recent Annual Report on Form 10-K for the year ended
December 31, 2012, and other subsequent filings. These filings are available
at www.sec.gov. We may, from time to time, make additional written and oral
forward-looking statements, including statements contained in our filings with
the Securities and Exchange Commission and our reports to shareholders. We do
not undertake to update any forward-looking statements that may be made from
time to time by or on our behalf.

SOURCE Biostar Pharmaceuticals, Inc.

Website: http://www.biostarpharmaceuticals.com
Contact: Biostar Pharmaceuticals, Inc., Ally Gong, +86-29-3368-6638,
office@aoxing-group.com
 
Press spacebar to pause and continue. Press esc to stop.